Learning Objectives:

1. Understand the evolving predictive role of the 21 gene assay in hormone positive breast cancer.

2. Appreciate multiple available adjuvant strategies for optimizing survival outcomes in hormone positive breast cancer.

3. Review pathological guidelines and considerations for diagnosis and management of HER2neu indeterminate breast cancers.


Session date: 
02/16/2021 - 7:00am to 8:00am CST
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Rita Nanda, MD: Associate Professor of Medicine, Director of Breast Oncology Program Jennifer Tseng, MD: Assistant Professor of Surgery Anne McCall, MD: Associate Professor of Radiation and Cellular Oncology, Medical Director, Medical Oncology for Silver